Statement: More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells.
Primary_evidence: Adverse Events 1:   Total: 14/67 (20.90%)   Febrile Neutropenia * 5/67 (7.46%)   Anemia * 3/67 (4.48%)   Neutropenia * 0/67 (0.00%)   Leukopenia * 0/67 (0.00%)   Sinus Tachycardia * 0/67 (0.00%)   Diarrhea * 2/67 (2.99%)   Nausea * 1/67 (1.49%)   Vomiting * 1/67 (1.49%)   Pancreatitis * 1/67 (1.49%)   Pyrexia * 1/67 (1.49%)   Bacteremia * 0/67 (0.00%)   Breast Cellulutis * 0/67 (0.00%) Adverse Events 2:   Total: 5/33 (15.15%)   Febrile Neutropenia * 0/33 (0.00%)   Anemia * 0/33 (0.00%)   Neutropenia * 0/33 (0.00%)   Leukopenia * 0/33 (0.00%)   Sinus Tachycardia * 0/33 (0.00%)   Diarrhea * 0/33 (0.00%)   Nausea * 1/33 (3.03%)   Vomiting * 1/33 (3.03%)   Pancreatitis * 0/33 (0.00%)   Pyrexia * 1/33 (3.03%)   Bacteremia * 0/33 (0.00%)   Breast Cellulutis * 0/33 (0.00%)